Director Peter Greenleaf filed a Form 4 with the SEC on November 4, 2026, disclosing the acquisition of stock options covering 160,000 shares of Altimmune, Inc. common stock, with a transaction date of November 2, 2026.

Key Highlights

  • Reporting person: Peter Greenleaf, listed as a Director of Altimmune, Inc. (NASDAQ:ALT)
  • Security acquired: Stock options (option to buy) covering 160,000 shares of Common Stock, par value $0.0001
  • Exercise price: $2.02 per share
  • Transaction date: November 2, 2026, with an expiration date of November 2, 2036
  • Price of derivative security: $0
  • Vesting schedule: Options vest in substantially equal monthly installments over 36 months following November 2, 2026, subject to continued service
  • Beneficial ownership following transaction: 160,000 derivative securities, held directly

Greenleaf Option Grant Details and Vesting Terms at Altimmune

According to the Form 4 filed on November 4, 2026, Peter Greenleaf, a director of Altimmune, Inc. (NASDAQ:ALT), acquired stock options to purchase 160,000 shares of the company's Common Stock (par value $0.0001) on November 2, 2026. The transaction was recorded under transaction code "A," indicating an acquisition. The exercise price of the options is $2.02 per share, and the options are set to expire on November 2, 2036.

The filing states that the options were acquired at a price of $0, and following the reported transaction, Greenleaf beneficially owns 160,000 derivative securities, held directly. No non-derivative securities transactions were reported in Table I of the filing.

As described in the filing's explanation of responses, "The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following November 2, 2026, subject to the reporting person's continued service through the applicable vesting date." The Form 4 was signed by Gregory Weaver as attorney-in-fact on November 4, 2026.

What Was Disclosed

Altimmune director Peter Greenleaf disclosed the acquisition of stock options covering 160,000 shares at an exercise price of $2.02, expiring November 2, 2036, vesting monthly over 36 months subject to continued service, with the form filed November 4, 2026.